METASTATIC PROSTATE ADENOCARCINOMA
Clinical trials for METASTATIC PROSTATE ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC PROSTATE ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC PROSTATE ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could high testosterone boost chemo in tough prostate cancers?
Disease control Recruiting nowThis study tests whether giving high levels of testosterone (much higher than normal) can make chemotherapy or a targeted radiation drug work better in men with advanced prostate cancer that has stopped responding to standard hormone therapy. About 69 participants will receive te…
Matched conditions: METASTATIC PROSTATE ADENOCARCINOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated May 17, 2026 04:41 UTC
-
Triple therapy may extend lives in metastatic prostate cancer
Disease control Recruiting nowThis study tests whether adding a chemotherapy drug (docetaxel) to the usual hormone therapy plus apalutamide helps men with prostate cancer that has spread to other parts of the body live longer. About 1,260 participants will receive either the standard two-drug treatment or the…
Matched conditions: METASTATIC PROSTATE ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated May 17, 2026 04:39 UTC
-
New combo aims to boost radiation's punch against hard-to-treat prostate cancer
Disease control Recruiting nowThis study tests whether giving a drug called abemaciclib before a targeted radiation therapy (177Lu-PSMA-617) can help treat metastatic castration-resistant prostate cancer that has stopped responding to other treatments. Abemaciclib may increase the number of targets (PSMA) on …
Matched conditions: METASTATIC PROSTATE ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Vadim S Koshkin • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New hope for Hard-to-Treat prostate cancer: drug combo trial launches
Disease control Recruiting nowThis study tests a combination of two drugs, ruxolitinib and enzalutamide, in men with advanced prostate cancer that has spread and no longer responds to hormone therapy. The goal is to find the safest dose and see if the combo can shrink tumors or lower PSA levels. About 20 part…
Matched conditions: METASTATIC PROSTATE ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control
Last updated May 11, 2026 20:49 UTC
-
New combo therapy aims to slow tough prostate cancer
Disease control Recruiting nowThis study tests a new treatment for men with a type of advanced prostate cancer that no longer responds to standard hormone therapy. The treatment combines a hormone therapy (testosterone) with a radioactive drug (radium-223) to try to slow cancer growth. About 47 men will recei…
Matched conditions: METASTATIC PROSTATE ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated May 11, 2026 20:48 UTC
-
Engineered immune cells take on Hard-to-Treat prostate cancer
Disease control Recruiting nowThis study tests whether a new cell therapy (STEAP1 CART) combined with the drug enzalutamide is safe and effective for men with advanced prostate cancer that has spread and stopped responding to standard treatments. About 48 participants will receive their own immune cells, modi…
Matched conditions: METASTATIC PROSTATE ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 06, 2026 16:01 UTC
-
New drug combo shows promise in halting prostate cancer growth
Disease control Recruiting nowThis study tests whether adding a targeted drug called talazoparib to standard hormone therapy can better control prostate cancer that has spread but still responds to hormones. About 70 men with metastatic castration-sensitive prostate cancer will receive the combination. The go…
Matched conditions: METASTATIC PROSTATE ADENOCARCINOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 01, 2026 15:58 UTC
-
New combo aims to make resistant prostate cancer cells visible to targeted radiation
Disease control Recruiting nowThis study tests whether the drug vorinostat can help men with a type of advanced prostate cancer that has low levels of a specific marker (PSMA). The marker is needed for a radioactive therapy called 177Lu-PSMA-617 to work. By giving vorinostat first, the hope is to increase PSM…
Matched conditions: METASTATIC PROSTATE ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Apr 30, 2026 15:49 UTC